Melbourne, 16 February 2026
CSL Seqirus, part of leading Australian biotechnology company CSL, has today announced that neffy® adrenaline (epinephrine) nasal spray is now available and has been approved for use in Australia for the emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over.1
Anaphylaxis occurs after exposure to an allergen, such as food, medications and insect bites and stings, and can be life threatening if not immediately treated with adrenaline. 3
Adrenaline rapidly reverses the effects of the condition by reducing throat swelling, opening the airways, and maintaining heart function and blood pressure.3
Anaphylaxis rates have increased over recent decades.4
Australia has one of the highest documented rates of anaphylaxis hospital admissions in the developed world.5 Between 2015 and 2020, Australian public hospitals reported a 51% increase in emergency department presentations and a 35% increase in hospitalisations due to anaphylaxis.6,7
Professor Connie Katelaris AM, leading NSW allergist, welcomes the registration and availability of neffy in Australia.
"The approval of neffy is very welcome as it gives patients and their doctors a nasal administration option and choice in managing their condition. It's the first time in over 30 years that a new way of administering adrenaline has been approved in Australia.
"Anaphylaxis is a difficult condition to manage with some patients reporting challenges. neffy has been available for some time overseas and now patients in Australia will have access."
Maria Said AM, Health Strategy and Advocacy Manager at Allergy & Anaphylaxis Australia, says the condition significantly impacts many Australians.
"Having a new treatment option which does not require injection will offer people at risk of anaphylaxis, and their treating doctor, the ability to choose an adrenaline device that best suits their needs from the range available.
"We know that people have to be extremely mindful of everyday things – such as eating at restaurants, attending social events, travelling or enjoying time outdoors. For parents of children with allergies, normal life experiences need to be planned for, including sleepovers, play dates, parties, air travel and school camps. Despite safety strategies being in place, accidents happen and people need to recognise an allergic reaction and respond quickly."
Dr Jonathan Anderson, CSL Seqirus Executive Medical Director – International and GP, says the company is hoping to expand access to the treatment.
"This is an important treatment option and so today is a proud day for CSL Seqirus as an Australian company," says Dr Anderson.
"We recognise the work by key Allergy Stakeholders in ensuring clinicians, consumers and school settings are prepared and supported for the introduction of neffy. We look forward to seeing decisionmakers assess our application for funding and working with them so that more Australians can access neffy."
Healthcare organisations are updating their resources and anaphylaxis education to include neffy. Please visit their websites for
